
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) through any online brokerage.
There are no as such competitors for ProShares Ultra Nasdaq Biotechnology.
There is no analysis for ProShares Ultra Nasdaq Biotechnology to provide a consensus price target.
The stock price for ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) is $79.28 last updated December 15, 2025 at 8:59 AM EST.
There are no upcoming dividends for ProShares Ultra Nasdaq Biotechnology.
ProShares Ultra Nasdaq Biotechnology does not have any upcoming earnings scheduled.
There is no upcoming split for ProShares Ultra Nasdaq Biotechnology.
| Sector | Healthcare |
| Category | Short Term Safe |
| Investment Style | Trading-Leveraged Equity |
| Fund Inception | Apr 6, 2010 |
| Managers | Tarak Dave Michael Neches |
| Definition | Fixed income fund portfolio contains a large percentage of securities with low duration and superior credit quality |
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.